Atrium Therapeutics Inc. (RNA)
NASDAQ: RNAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
RNA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $149.27M
- EPS (TTM)
- -$5.22
- Dividend yield
- None
- 52-week range
- 6.36 – 16.77
- Day range
- 6.88 – 7.44
- Volume / Avg
- 319.59K / 297.20K
- Beta
- —
- Shares outstanding
- 21.57M
52-week range
RNA stock today
Atrium Therapeutics (RNA) closed at $6.92 on Nov 20, down 0.86% (-$0.06), versus the S&P 500's 3.70% decline. Shares are 58.7% below their 52-week high of $16.77, set on Mar 5, 2026 and 8.8% above the 52-week low of $6.36, near the bottom of the past year's range. Atrium Therapeutics has posted a net loss over the last twelve months (EPS of -$5.22), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Atrium Therapeutics
Company profileAtrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Ms. Kathleen P. Gallagher
- Headquarters
- San Diego, CA
- Website
- atriumtherapeutics.com
Analyst forecast
ForecastConsensus (5 analysts)
strong_buy
Avg. price target
$22.00+217.92%
- Strong buy 0
- Buy 5
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.25 vs $-1.15
- Surprise
- +78.26%
RNA news
All RNA news- Atrium Therapeutics Doses First Patient in Corventis™, the First Interventional Clinical Trial for People Living with PRKAG2 SyndromePR Newswire
- Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)PR Newswire
- Atrium Therapeutics Announces $50 Million Private PlacementPR Newswire
Atrium Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ELDNEledon Pharmaceuticals Inc. | 1.78 | -6.32% | $150.34M | vs RNA |
| IFRXInflaRx N.V. | 1.04 | -4.59% | $153.26M | vs RNA |
| VRXAVeraxa Biotech AG | 1.04 | +0.97% | $147.06M | vs RNA |
| PRQRProQR Therapeutics N.V. | 1.04 | -0.95% | $146.98M | vs RNA |
| ORMPOramed Pharmaceuticals Inc. | 3.57 | -3.25% | $155.24M | vs RNA |
| BBOTBridgeBio Oncology Therapeutics Inc. | 1.81 | -2.69% | $145.25M | vs RNA |
| EMISEmmis Acquisition Corp. Class A | 10.36 | +0.15% | $163.36M | vs RNA |
| ALXOALX Oncology Holdings Inc. | 1.06 | +3.92% | $137.03M | vs RNA |
Indexes, lists and sector
Atrium Therapeutics stock FAQ
What is Atrium Therapeutics's stock price today?
RNA last traded at $6.92 as of Nov 20, 4:00 PM EST, down 0.86% on the day. Prices are delayed at least 15 minutes.
Who is Atrium Therapeutics's CEO?
Ms. Kathleen P. Gallagher is the chief executive officer of Atrium Therapeutics Inc..
What is the RNA 52-week high?
The 52-week high for RNA is $16.77 and the 52-week low is $6.36. The stock is currently 58.7% below its high.